Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE: Reduced Chemotherapy Cycles + Pembrolizumab in First-Line R/M HNSCC
NCT06557889Phase 2Active, not recruiting
- Sponsor
- Institut Claudius Regaud
- Start
- Oct 2024
- Primary completion
- Apr 2033
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, Cisplatin micelle injection (HA132), carboplatin, fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by Institut Claudius Regaud. Started Oct 2024; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06557889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557889.